MacroGenics Inc (MGNX) company profile
Close on Nov 17, 2026Market cap $130.59MP/E –Yield –
About MacroGenics
Pharmaceutical Preparations, SIC 2834
MacroGenics, Inc. is a clinical-stage biopharmaceutical company that develops antibody-based therapeutics for cancer treatment. Utilizing proprietary multi-specific platforms such as DART and TRIDENT alongside licensed antibody-drug conjugate technologies, the company designs therapeutics for solid tumors and hematologic malignancies. Its pipeline includes investigational candidates like lorigerlimab, MGC026, and MGC028. Beyond proprietary drug development, the company generates revenue and collaborative funding by out-licensing product candidates to global biopharmaceutical partners and providing contract development and manufacturing services to external clients and commercial collaborators.
The company operates a commercial-scale current good manufacturing practice (cGMP) antibody production facility situated at its headquarters in Maryland. It maintains a worldwide patent presence, holding 58 issued patents and 24 pending applications in the United States, as well as 681 issued patents and 283 pending applications across various international jurisdictions. MacroGenics also engages in strategic drug development partnerships with major international pharmaceutical enterprises, including collaborations supporting global product development and commercialization initiatives.
Summary of the business section of MacroGenics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- MacroGenics Inc
- Founded
- 2000
- Headquarters
- Rockville, MD
- Address
- 9704 Medical Center Drive 20850
- Phone
- (301) 251-5172
- Website
- macrogenics.com
- Employees
- 293, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Tysons, Virginia
Stock & identifiers
- Ticker
- MGNX
- Exchange
- Nasdaq
- IPO date
- Oct 11, 2013
- Shares outstanding
- 64M, Aug 8, 2026
- Public float
- $73.90M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1125345
- CUSIP
- 556099109
- ISIN
- US5560991094
- FIGI
- BBG000BM2SF8
- Share class FIGI
- BBG001S9C8R7
- LEI
- 5493001KJQUA83L8MH79
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Eric Blasius Risser | President and CEO, Director | 77,169 |
| Ezio Bonvini | Sr VP, Research & CSO | 201,349 |
| Jeffrey Stuart Peters | Senior VP, GC, and Secretary | 0 |
| Beth Ann Smith | VP, Controller & Treasurer | 13,204 |
| James Karrels | SVP and CFO | 306,368 |
| Thomas Spitznagel | Sr VP, Technical Ops | 38,543 |
| Stephen L. Eck | Chief Medical Officer | 29,377 |
| Emil Kuriakose | Director | – |
| Michael Vasconcelles | Director | – |
| William K. Heiden | Director | 114,750 |
| Scott Koenig | Director | 1,294,720 |
| Scott Thomas Jackson | Director | 14,750 |
| Jay Philip Siegel | Director | 14,750 |
| Karen Jean Ferrante | Director | 14,750 |
| Federica F. O'Brien | Director | 14,750 |
| Edward Hurwitz | Director | 1,752,820 |
| Meenu Chhabra | Director | 14,750 |
| Margaret Liu | Director | 14,750 |
| David C. Stump | Director | 14,750 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Current PEO | $2.08M | $1.48M | $1.19M | $7 | – |
| FY2025 Former PEO | $952.96K | $192.14K | $1.19M | $7 | – |
| FY2024 Current PEO | $0 | $0 | $2.51M | $14 | – |
| FY2024 Former PEO | $6.40M | $1.78M | $2.51M | $14 | – |
| FY2023 Current PEO | $0 | $0 | $1.66M | $42 | – |
| FY2023 Former PEO | $3.71M | $6.49M | $1.66M | $42 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| Eric Risser President, Chief Executive Officer and Director | $561.57K | $150.00K | $52.00K | $1.05M | $251.90K | $14.00K | $2.08M | – |
| Scott Koenig, M.D., Ph.D. Former Chief Executive Officer and current Director | $477.12K | – | – | – | – | $475.84K | $952.96K | -85% |
| Ezio Bonvini Senior Vice President, Research and Chief Scientific Officer | $533.20K | $150.00K | $54.60K | $288.04K | $184.20K | $14.00K | $1.22M | – |
| James Karrels Senior Vice President and Chief Financial Officer | $506.55K | $150.00K | $49.40K | $254.28K | $175.00K | $14.00K | $1.15M | -51% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 11, 2013
- Offer price
- $16.00
- Securities offered
- 5,000,000
- Gross proceeds
- $80.00M
- Exchange
- Nasdaq
- First trading day
- Oct 10, 2013
- First-day close
- $24.99+56.2%
- Lock-up ends (est.)
- Apr 8, 2014
“Per share Total Initial public offering price $ 16.00 $ 80,000,000 Underwriting discounts and commissions 1 $ 1.12 $ 5,600,000 Proceeds before expenses, to us $ 14.88 $ 74,400,000 1 We refer you to “Underwriting” beginning on page 158 of this prospectus for additional information regarding total underwriter compens”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of February 28, 2026, we had 293 full-time employees, 245 of whom were primarily engaged in research, development and manufacturing activities, an d 61 of whom had an M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 7, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Oct 11, 2013 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 7, 2013 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?